Literature DB >> 21517757

Regulation of expression and function of IDO in human dendritic cells.

A Heitger1.   

Abstract

In the human immune system, IDO expression and activity (IDO competence), are preferentially found in the antigenpresenting cell population, of which dendritic cells (DCs) represent an essential part. As will be comprehensively reviewed, IDO competence in human DCs, in general, is induced by molecules such as interferon-γ, which otherwise initiate immunity. IDO activity therefore, can be interpreted as a negative feedback pathway that limits uncontrolled immune responses. Because of its potent immunosuppressive effects (down-regulation of T cell responses or the expansion of T cell regulatory activity), IDO competence in human DCs is tightly regulated, at the transcriptional, translational and post-translational levels. I will critically discuss the experimental prerequisites and limits of attributing IDO competence to a mechanism of immunosuppression and examine, whether IDO competence itself can be viewed as mediating immunosuppression, or as representing one component among other immunosuppressive factors, involved in tolerogenic function of DCs. Finally, the newly emerging concepts of manipulating IDO competence as a therapy for either augmenting immune responses, such as in cancer, or down-regulating immune responses, such as in transplantation, will be summarized.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21517757     DOI: 10.2174/092986711795656018

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  15 in total

Review 1.  The role of placental tryptophan catabolism.

Authors:  Peter Sedlmayr; Astrid Blaschitz; Roland Stocker
Journal:  Front Immunol       Date:  2014-05-19       Impact factor: 7.561

2.  Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma.

Authors:  M L Madariaga; S G Michel; G M La Muraglia; M Sekijima; V Villani; D A Leonard; H J Powell; J M Kurtz; E A Farkash; R B Colvin; J S Allan; C L Cetrulo; C A Huang; D H Sachs; K Yamada; J C Madsen
Journal:  Am J Transplant       Date:  2015-03-30       Impact factor: 8.086

3.  Immunosuppressive mechanisms of regulatory dendritic cells in cancer.

Authors:  Galina V Shurin; Yang Ma; Michael R Shurin
Journal:  Cancer Microenviron       Date:  2013-06-09

Review 4.  Placental expression of indoleamine 2,3-dioxygenase.

Authors:  Peter Sedlmayr; Astrid Blaschitz
Journal:  Wien Med Wochenschr       Date:  2012-05

5.  CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk.

Authors:  Edda Mayer; Markus Hölzl; Sarah Ahmadi; Barbara Dillinger; Nina Pilat; Dietmar Fuchs; Thomas Wekerle; Andreas Heitger
Journal:  Int Immunopharmacol       Date:  2013-02-20       Impact factor: 4.932

Review 6.  The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity.

Authors:  Jacques C Mbongue; Dequina A Nicholas; Timothy W Torrez; Nan-Sun Kim; Anthony F Firek; William H R Langridge
Journal:  Vaccines (Basel)       Date:  2015-09-10

Review 7.  Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases.

Authors:  Yuki Murakami; Masato Hoshi; Yukio Imamura; Yuko Arioka; Yasuko Yamamoto; Kuniaki Saito
Journal:  Mediators Inflamm       Date:  2013-02-18       Impact factor: 4.711

8.  Metabolomics changes in a rat model of obstructive jaundice: mapping to metabolism of amino acids, carbohydrates and lipids as well as oxidative stress.

Authors:  Yue Long; Xin Dong; Yawei Yuan; Jinqiang Huang; Jiangang Song; Yumin Sun; Zhijie Lu; Liqun Yang; Weifeng Yu
Journal:  J Clin Biochem Nutr       Date:  2015-06-04       Impact factor: 3.114

Review 9.  Targeting the indoleamine 2,3-dioxygenase pathway in cancer.

Authors:  Yong Wha Moon; Joud Hajjar; Patrick Hwu; Aung Naing
Journal:  J Immunother Cancer       Date:  2015-12-15       Impact factor: 13.751

10.  Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.

Authors:  Laïla-Aïcha Hanafi; Dominique Gauchat; Jessica Godin-Ethier; David Possamaï; Jean-Baptiste Duvignaud; Denis Leclerc; Nathalie Grandvaux; Réjean Lapointe
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.